Ivonescimab
Ivonescimab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Thymus Carcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
3 项
已进入 III/IV 期
12 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Jonsson Comprehensive Cancer Center
- Harbin Medical University
- QuantumLeap Healthcare Collaborative
- Akeso
- M.D. Anderson Cancer Center
- Memorial Sloan Kettering Cancer Center
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- SWOG Cancer Research Network
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、法国、日本、比利时、加拿大、德国、Greece、Hungary、意大利、Mexico、Poland
正在招募患者的 Ivonescimab 研究
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
II 期招募中中国NCT06196697I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
II 期招募中美国NCT01042379Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
III 期招募中中国NCT06928389Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
II 期招募中美国NCT06567314A Study of Ivonescimab in People With Endometrial and Cervical Cancers
II 期招募中美国NCT06925724Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
II 期招募中中国NCT06848842Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
II 期招募中美国NCT07393555First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
I 期 / II 期招募中中国NCT06877650Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
II 期招募中美国NCT07405190A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
III 期招募中中国NCT07010263Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
II 期招募中法国NCT06840834Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
II 期招募中中国NCT07070479Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
II 期招募中中国NCT07647016A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
II 期招募中中国NCT07381075A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
II 期招募中中国NCT06444009SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer
II 期招募中中国NCT06402435Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
I 期 / II 期招募中中国NCT07885319A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
I 期 / II 期招募中美国NCT07594522A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
I 期 / II 期招募中美国日本NCT07602855Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients
II 期招募中中国NCT07809893Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma
II 期招募中中国NCT06875076Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
II 期招募中中国NCT07188103Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
III 期招募中美国比利时加拿大中国NCT06767514Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
I 期招募中中国NCT06868732
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。